CHESTNUT RIDGE, N.Y., May 27, 2015 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. today announced that the United States Court of Appeals for the Federal Circuit has upheld the U.S. District Court for the District of Delaware's earlier ruling that Par's filing of an Abbreviated New Drug Application for its generic version of Novartis' Exelon® Patch (rivastigmine transdermal system) does not infringe United States Patent Nos. 6,316,023 or 6,335,031. The appeals court also affirmed the district court's finding that the patents are not invalid. As a result of this decision, Par can launch its product upon receiving final approval from the United States Food and Drug Administration.
The Exelon Patch® is indicated for treatment of mild, moderate, and severe dementia of the Alzheimer's type, and mild to moderate dementia associated with Parkinson's disease. According to IMS Health data, annual U.S. sales of the Exelon® Patch are approximately $626 million. "Exelon Patch" is a registered trademark of Novartis AG Corporation.
About Par Pharmaceutical Companies, Inc.
Par is a specialty pharmaceutical company that develops, manufactures and markets safe, innovative and cost-effective pharmaceuticals that help improve patient quality of life. Par Pharmaceutical offers a line of high-barrier-to-entry generic drugs, while Par Specialty Pharmaceuticals provides niche, innovative brands. Par Sterile Products develops, manufactures and markets both branded and generic aseptic injectable pharmaceuticals. For press release and other company information, visit www.parpharm.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/par-pharmaceutical-receives-favorable-appeals-court-ruling-in-generic-exelon-patch-litigation-300089043.html
SOURCE Par Pharmaceutical Companies
Help employers find you! Check out all the jobs and post your resume.
